Boom assembly and method of assembly thereof
US-11148915-B2 · Oct 19, 2021 · US
US9238571B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9238571-B2 |
| Application number | US-201013498600-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 21, 2010 |
| Priority date | Sep 30, 2009 |
| Publication date | Jan 19, 2016 |
| Grant date | Jan 19, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The instant invention relates to pharmaceutical compositions containing c-Met kinase inhibitors. Also disclosed are processes for making said pharmaceutical compositions.
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising from 30% to 35% by weight of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2- ylmethyl)methanesulfonamide or a pharmaceutically acceptable salt thereof, 40% to 45% by weight of an acidulant, 20% to 25% by weight of a diluent, 1.0% to 5.0% by weight of a disintegrant and from 0.5% to 2.0% by weight of a lubricant, wherein the weight ratio of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide to acidulant is selected from within a range of 0.3 to 5.0. 2. The pharmaceutical composition of claim 1 wherein the acidulent is selected from the group consisting of acetic, adipic, benzenesulphonic, benzoic, caprylic, cinnamic, citric, ethanedisulphonic, tartaric, ascorbic, maleic, glutamic, lactic, oxalic, L-Aspartic, 2-hydroxyethanesulfonic, pamoic, malonic, gentisic, salicylic, fumaric, glucoheptoic, gluconic, glucuronic, hippuric, lactobionic, laurylsulfuric, malic, malonic, mandelic, methanesulphonic, propionic, stearic, toluenesulphonic, undecylenic, camphorsulfonic and oleic acid. 3. The pharmaceutical composition of claim 1 wherein the diluent is selected from the group consisting of microcrystalline cellulose, lactose, mannitol, calcium phosphate, calcium carbonate, magnesium carbonate, sucrose, glucose, sorbitol, calcium sulfate, powdered cellulose, silicified microcrystalline cellulose, cellulose acetate, compressible sugar, dextrates, dextrin, dextrose, ethylcelluose, fructose, glyceryl palmitostearate, kaolin, lactitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium-chain triglycerides, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, tragacanth, trehalose, xylitol and starch. 4. The pharmaceutical composition of claim 1 wherein the disintegrant is selected from the group consisting of croscarmellose sodium, starch, crospovidone, sodium starch glycolate, calcium carbonate, sodium carbonate, magnesium carbonate, alginic acid, tribasic calcium phosphate, calcium carboxymethylcellulose, sodium carboxymethylcellulose, powdered cellulose, chitosan, colloidal silicon dioxide, guar gum, hydroxypropyl cellulose, magnesium aluminium silicate, methylcellulose, povidone, and sodium alginate. 5. The pharmaceutical composition of claim 1 wherein the lubricant is selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumerate, talc, calcium stearate, glycerin monostearate, glyceryl behenate, glyceryl palmitostearate, magnesium lauyl sulfate, medium chain triglycerides, poloxamer, sodium benzoate, sodium chloride, sodium lauryl sulfate and zinc stearate. 6. The pharmaceutical composition of claim 1 wherein the acidulant is citric acid, the diluent is microcrystalline cellulose, the disintegrant is croscarmellose sodium and the lubricant is magnesium stearate. 7. A method of improving the absorption of a c-Met kinase inhibitor by administering to a patient the pharmaceutical composition of claim 1 .
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
and movable to take account of variations of load or of variations of length of jib · CPC title
Organic compounds, e.g. phospholipids, fats · CPC title
resulting in granules or microspheres of the matrix type containing more than 5% of excipient · CPC title
Jib-cranes adapted for attachment to standard vehicles, e.g. agricultural tractors · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.